The company plans to introduce another medication in oncology
US pharmaceutical major Eli Lilly has launched once-a-week diabetes treatment drug under the brand name ‘Trulicity.’ The company has launched the product after receiving the regulatory approval for the same in India.
Edgard Olaizola, Managing Director, Eli Lilly India said, “The medicine is an injectable medication and belongs to a class called GLP-1 receptor agonists. It is not a insulin.”
Trulicity comes in a single-dose pen and is designed to improve the blood sugar control in adults with type II diabetes.
“India is the third country after Japan and the UAE in Asia and it (Trulicity) is already available in the US and Europe. This complements our diabetes portfolio in India,” Olaizola said.
For Eli Lilly, diabetes is the biggest segment with “about 85 per cent of our sales in India coming from diabetes and we are growing double digit and growing our market share,” he added.
After diabetes, the other important segment is oncology. The others are osteoporosis and human growth hormone, he added.
The company is also looking to introduce another medication in oncology. The company expects to introduce the product by next year, he added.